Transforming drug manufacturing, starting with insulin

rBIO has developed a proprietary insulin manufacturing process and licensing platform designed to increase production output and improve the economics of essential peptide drugs.

The company’s initial drug focus is insulin, with a licensing-first model designed for qualified regional and strategic partners.

rBIO in a nutshell:

Insulin-first manufacturing platform
Proprietary process designed to increase output
Scale-up path toward 1,000L production
Licensing model for regional and global partners
Experienced leadership and investor-aligned commercialization plan

rBIO CEO Dr. Deen Bakthavatsalam explains the company’s insulin manufacturing process and licensing model, which aims to improve the economics of essential peptide drugs.

Request investor materials

Business Model

A licensing platform for insulin manufacturing

rBIO is built around a simple commercial premise: by improving insulin production economics, we will create value for patients, manufacturers, licensees and investors.

The company’s proprietary manufacturing process increases insulin output, supports lower-cost production, and creates a repeatable licensing model for qualified partners.

The problem we address:

Complex manufacturing drives high prices

Insulin remains a large, essential drug category, but manufacturing complexity continues to drive cost, margin pressure and supply vulnerability.

For manufacturers and regional partners, the opportunity is clear: a more efficient insulin production process can improve commercial economics while supporting broader patient access.

Investor relevance

Large essential-drug market
Persistent manufacturing inefficiency
Supply pressure as major manufacturers shift focus
Need for qualified regional production capacity
Potential for licensing-driven scale

rBIO’s solution

A proprietary process designed to increase output

rBIO’s process combines proprietary manufacturing know-how with an insulin-first development strategy.

The platform is designed to double the rate of insulin production compared to current industry production, subject to final technical and public-claims approval.